Ascentage Pharma Group International Unsponsored ADR (AAPG)
NASDAQ:AAPG
Want to see AAPG full AI Analyst Report?
Top Page
Ascentage Pharma Group International Unsponsored ADR
(NASDAQ:AAPG)
Select Model
Select Model
Rating:40Underperform
Price Target:
$16.50
▼(-39.78% Downside)
Action:Downgraded
Date:05/04/26
The score is primarily constrained by weak financial performance driven by persistent and worsening losses and significant cash burn, despite strong revenue growth and high gross margins. Technicals also reflect a weak trend with negative momentum. Valuation is further pressured by a negative P/E and no dividend yield data.
Positive Factors
High gross margins and revenue growth
Sustained high gross margins and meaningful top-line expansion provide structural operating leverage typical of successful biotech platforms. If R&D and SG&A are disciplined, these margins support scalability and long-term product commercialization economics beyond short-term volatility.
Negative Factors
Severe cash burn
Very large, persistent negative operating and free cash flow creates sustained reliance on external financing. Over months this raises dilution and execution risk, can constrain trial progression and commercialization ramp, and elevates capital markets dependency when funding windows are narrow.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins and revenue growth
Sustained high gross margins and meaningful top-line expansion provide structural operating leverage typical of successful biotech platforms. If R&D and SG&A are disciplined, these margins support scalability and long-term product commercialization economics beyond short-term volatility.
Read all positive factors
Ascentage Pharma Group International Unsponsored ADR (AAPG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.55B
Dividend YieldN/A
Average Volume (3M)8.43K
Price to Earnings (P/E)―
Beta (1Y)0.74
Revenue Growth-41.19%
EPS Growth-159.09%
CountryUS
Employees567
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-13.84
Shares Outstanding93,388,940
10 Day Avg. Volume7,086
30 Day Avg. Volume8,425
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)12.33
Price to Sales (P/S)29.25
P/FCF Ratio-13.59
Enterprise Value/Market Cap6.63
Enterprise Value/Revenue18.04
Enterprise Value/Gross Profit21.46
Enterprise Value/Ebitda-9.20
Forecast
1Y Price Target
$42.05Price Target Upside53.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.03
Revenue Forecast (FY)$132.89M
Ascentage Pharma Group International Unsponsored ADR Business Overview & Revenue Model
Company Description
Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, in...
How the Company Makes Money
null...
Ascentage Pharma Group International Unsponsored ADR Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 558.48M | 980.65M | 221.98M | 209.71M | 27.91M |
| Gross Profit | 426.75M | 951.57M | 191.44M | 187.71M | 24.58M |
| EBITDA | -1.10B | -237.63M | -743.61M | -786.97M | -798.34M |
| Net Income | -1.21B | -405.43M | -925.64M | -882.92M | -782.42M |
Balance Sheet | |||||
| Total Assets | 3.97B | 2.62B | 2.50B | 2.83B | 2.94B |
| Cash, Cash Equivalents and Short-Term Investments | 2.47B | 1.24B | 1.07B | 1.48B | 1.71B |
| Total Debt | 1.98B | 1.67B | 1.80B | 1.79B | 1.08B |
| Total Liabilities | 2.63B | 2.34B | 2.43B | 2.42B | 1.71B |
| Stockholders Equity | 1.33B | 264.19M | 60.42M | 408.66M | 1.23B |
Cash Flow | |||||
| Free Cash Flow | -1.20B | -135.65M | -782.92M | -890.88M | -1.04B |
| Operating Cash Flow | -1.17B | -111.36M | -726.08M | -653.91M | -604.68M |
| Investing Cash Flow | -1.00B | -362.04M | 21.92M | -384.61M | -466.52M |
| Financing Cash Flow | 2.54B | 314.77M | 368.75M | 619.27M | 1.78B |
Ascentage Pharma Group International Unsponsored ADR Technical Analysis
Negative
27.40
Price Trends
37.24
Negative
38.97
Negative
Market Momentum
-1.44
Positive
34.89
Neutral
11.49
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AAPG, the sentiment is Negative. The current price of 27.4 is below the 20-day moving average (MA) of 34.27, below the 50-day MA of 37.24, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of -1.44 indicates Positive momentum. The RSI at 34.89 is Neutral, neither overbought nor oversold. The STOCH value of 11.49 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AAPG.
Ascentage Pharma Group International Unsponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $7.26B | -64.04 | -17.76% | ― | -64.36% | -302.09% | |
58 Neutral | $7.26B | -14.24 | -68.16% | ― | ― | -1.22% | |
55 Neutral | $3.78B | -7.52 | -43.96% | ― | 4905.26% | -34.49% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $7.44B | -28.00 | -25.02% | ― | -12.58% | -15.21% | |
47 Neutral | $1.41B | -5.33 | -85.61% | ― | ― | -68.11% | |
40 Underperform | $1.55B | -8.72 | -123.61% | ― | -41.19% | -159.09% |
* Healthcare Sector Average
AAPG
Ascentage Pharma Group International Unsponsored ADR
17.12
-20.03
-53.92%
PTGX
Protagonist Therapeutics
112.86
59.50
111.51%
CRNX
Crinetics Pharmaceuticals
35.87
5.96
19.93%
IMVT
Immunovant
35.34
19.87
128.44%
KYMR
Kymera Therapeutics
90.43
44.14
95.36%
MLTX
MoonLake Immunotherapeutics
19.21
-25.66
-57.19%
Ascentage Pharma Group International Unsponsored ADR Corporate Events
Ascentage Pharma Showcases First Pediatric Alrizomadlin Data at ASCO 2026
Jun 1, 2026
Ascentage Pharma reported on May 31, 2026 that it presented its first dataset for alrizomadlin (APG-115), an orally administered, highly selective MDM2-p53 inhibitor, in pediatric solid tumors at the 62nd American Society of Clinical Oncology Annu...
Ascentage Pharma to Present 17 Hematology Clinical Updates at June 2026 EHA Congress
May 13, 2026
On May 12, 2026, Ascentage Pharma Group International, a global biopharmaceutical company specializing in innovative oncology therapies, announced that 17 clinical advances from its core assets will be showcased at the 31st European Hematology Ass...
Ascentage Pharma to Highlight Oncology Portfolio at May–June 2026 Investor Conferences
May 12, 2026
Ascentage Pharma Group International is a global, commercial-stage biopharmaceutical company specializing in innovative oncology therapies, including apoptotic pathway inhibitors, next-generation kinase inhibitors and protein degraders. Its lead p...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.